Legend Biotech (LEGN) Cash from Investing Activities (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Cash from Investing Activities data on file, last reported at $638.5 million in Q4 2025.

• In Q4 2025, Cash from Investing Activities rose 826.39% year-over-year to $638.5 million; the TTM figure through Dec 2025 stood at $709.6 million (up 183.42% YoY), while the FY2025 annual figure was $709.6 million, up 183.42% from the prior year.
• Cash from Investing Activities grew to $638.5 million in Q4 2025, from -$20.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $638.5 million in Q4 2025 and bottomed at -$695.6 million in Q2 2024.
• A 5-year average of -$35.8 million and a median of -$83.1 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 4807.27% — and 2025, when it surged 826.39%.
• Year by year, Cash from Investing Activities stood at -$195.0 million in 2021, then surged by 59.82% to -$78.3 million in 2022, then jumped by 620.15% to $407.5 million in 2023, then sank by 121.57% to -$87.9 million in 2024, then surged by 826.39% to $638.5 million in 2025.
• The last three Cash from Investing Activities figures came in at $638.5 million (Q4 2025), -$20.0 million (Q3 2025), and -$165.5 million (Q2 2025), per Business Quant data.

Peer Comparison